ePrints

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Lookup NU author(s): Professor Graham Jackson

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10(-4)) after treatment is an independent predictor of progression-free survival (PFS), but not always of overall survival (OS). However, MRD level is a continuous variable, and the predictive value of the depth of tumor depletion was evaluated in 397 patients treated intensively in the Medical Research Council Myeloma IX study. There was a significant improvement in OS for each log depletion in MRD level (median OS was 1 year for >= 10%, 4 years for 1% to <10%, 5.9 years for 0.1% to <1%, 6.8 years for 0.01% to <0.1%, and more than 7.5 years for <0.01% MRD). MRD level as a continuous variable determined by flow cytometry independently predicts both PFS and OS, with approximately 1 year median OS benefit per log depletion. The trial was registered at www.isrctn.com as #68454111.

Publication metadata

Author(s): Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT, Cook G, Jackson GH, Morgan GJ, Child JA, Owen RG

Publication type: Article

Publication status: Published

Journal: Blood

Year: 2015

Volume: 125

Issue: 12

Pages: 1932-1935

Print publication date: 19/03/2015

Online publication date: 19/03/2015

Acceptance date: 16/01/2015

ISSN (print): 0006-4971

ISSN (electronic): 1528-0020

Publisher: American Society of Hematology

URL: http://dx.doi.org/10.1182/blood-2014-07-590166

DOI: 10.1182/blood-2014-07-590166

Altmetrics

Share